Answers are grounded in this paper and cite their sources.
Reveals that targeting lineage plasticity improves treatment outcomes in neuroendocrine bladder carcinoma, suggesting new therapeutic options.
Neuroendocrine bladder carcinoma (NEBC) is an aggressive and therapy-resistant cancer with poor prognosis. Although lineage plasticity drives urothelial-to-neuroendocrine transdifferentiation, intermediate states remain poorly characterized. Through transcriptomic profiling of public datasets, we define a lineage plasticity-associated signature in bladder cancer. We analyze 64,756 in-house and 201,720 public single-cell transcriptomes from NEBC and urothelial carcinoma (UC), identifying TPX2high bladder cancer cell subpopulation with increased lineage plasticity, supported by multi-cohort histological validation. TPX2high cells lack canonical neuroendocrine markers and are associated with adverse clinical outcomes. TPX2high cells exhibit dysregulated cell cycle progression and occupy a suppressive niche associated with CD8⁺ T cell exhaustion. In vitro and in vivo, TPX2 promotes lineage plasticity and induces T cell exhaustion. In preclinical patient-derived organoids (PDOs) and patient-derived xenograft (PDX) models, CDK4/6 inhibition plus immune checkpoint blockade demonstrates potent antitumor efficacy. Overall, our findings suggest this combination therapy as a promising therapeutic strategy for TPX2high and NEBC patients.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: